The estimated Net Worth of Argenio David Z D is at least $1.46 Milhão dollars as of 24 May 2017. Argenio D owns over 2,674 units of Simulations Plus stock worth over $1,102,678 and over the last 20 years Argenio sold SLP stock worth over $362,105.
Argenio has made over 8 trades of the Simulations Plus stock since 2011, according to the Form 4 filled with the SEC. Most recently Argenio sold 2,674 units of SLP stock worth $31,232 on 24 May 2017.
The largest trade Argenio's ever made was selling 21,326 units of Simulations Plus stock on 22 May 2017 worth over $247,168. On average, Argenio trades about 2,771 units every 78 days since 2004. As of 24 May 2017 Argenio still owns at least 33,608 units of Simulations Plus stock.
You can see the complete history of Argenio D stock trades at the bottom of the page.
Argenio's mailing address filed with the SEC is 1220 W AVENUE J, , LANCASTER, CA, 93534.
Over the last 21 years, insiders at Simulations Plus have traded over $70,055,940 worth of Simulations Plus stock and bought 24,000 units worth $1,395,840 . The most active insiders traders include Walter Swoltosz Virginia E ..., Walter S Woltosz, eMomoko A Beran. On average, Simulations Plus executives and independent directors trade stock every 37 days with the average trade being worth of $571,025. The most recent stock trade was executed by Jill Fiedler Kelly on 9 September 2024, trading 2,250 units of SLP stock currently worth $21,848.
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
Simulations Plus executives and other stock owners filed with the SEC include: